[{"orgOrder":0,"company":"Federal University of Minas Gerais","sponsor":"Baxter Healthcare Corporation | Medtronic plc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Federal University of Minas Gerais","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federal University of Minas Gerais \/ Baxter Healthcare Corporation | Medtronic plc","highestDevelopmentStatusID":"11","companyTruncated":"Federal University of Minas Gerais \/ Baxter Healthcare Corporation | Medtronic plc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fluvastatin Sodium","moa":"HMG-CoA reductase","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"PAKISTAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medical Corps, Israel Defense Force \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gabrail Cancer Center Research \/ Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences"},{"orgOrder":0,"company":"University of Florence","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"University of Florence","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florence \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Florence \/ Merck & Co"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Heart Health Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Xuezhikang","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Heart Health Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heart Health Research Center \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Heart Health Research Center \/ AstraZeneca"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tralement is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Manganese Poisoning.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 10, 2023

                          Lead Product(s) : Tralement

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tralement is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Manganese Poisoning.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 22, 2022

                          Lead Product(s) : Tralement

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Heart Health Research Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Heart Health Research Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Xuezhikang is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lipid Metabolism Disorders.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          February 14, 2022

                          Lead Product(s) : Xuezhikang

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          December 17, 2021

                          Lead Product(s) : Insulin

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Gabrail Cancer Center Research

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Gabrail Cancer Center Research

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Orlistat

                          Therapeutic Area : Pharmacology/Toxicology

                          Study Phase : Phase IV

                          Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Polybrominated Biphenyl Poisoning.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 11, 2018

                          Lead Product(s) : Orlistat

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Medical Corps, Israel Defense Force

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Medical Corps, Israel Defense Force

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 01, 2017

                          Lead Product(s) : Scopolamine

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University of Florence

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Florence

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Sugammadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Delayed Emergence from Anesthesia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 04, 2016

                          Lead Product(s) : Sugammadex Sodium

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Federal University of Minas Gerais

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Federal University of Minas Gerais

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Propofol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Delayed Emergence from Anesthesia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 16, 2015

                          Lead Product(s) : Propofol

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Baxter Healthcare Corporation | Medtronic plc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Fluvastatin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lipid Metabolism Disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 12, 2012

                          Lead Product(s) : Fluvastatin Sodium

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank